Baicalin and lung diseases.

Area of Science:

• Pharmacology
• Natural Products Chemistry
• Respiratory Medicine

Background:

• Natural products are widely studied for therapeutic properties.
• Baicalin (BIA), a flavonoid glycoside from Scutellaria baicalensis, demonstrates lung-protective effects in preclinical models.
• Existing research highlights BIA's potential in managing diverse lung pathologies.

Purpose of the Study:

• To comprehensively review and analyze existing data on Baicalin's lung-protective functions.
• To evaluate BIA's efficacy against various lung injuries and diseases.
• To identify key molecular targets and pathways involved in BIA's therapeutic actions.

Main Methods:

• Systematic review and data analysis of preclinical studies on Baicalin and lung protection.
• Examination of BIA's effects in models of acute lung injury, fibrosis, pulmonary embolism, COPD, and lung cancer.
• Investigation of molecular mechanisms including inflammation, oxidative stress, apoptosis, and specific signaling pathways.

Main Results:

• Baicalin (BIA) demonstrated protective effects against acute lung injury, lung fibrosis, pulmonary embolism, and COPD-related lung remodeling.
• BIA exhibited anticancer activity in lung cancer models and attenuated infection-induced lung damage.
• Key mechanisms involve suppression of inflammation, oxidative stress, immune response, and apoptosis via pathways like Nrf2/HO-1, PI3K/Akt, NF-κB, and NLRP3.

Conclusions:

• Baicalin (BIA) shows significant therapeutic promise for a range of lung diseases.
• BIA's efficacy is mediated through the modulation of critical inflammatory, oxidative stress, and apoptotic pathways.
• Clinical translation of BIA for lung diseases is recommended, contributing to treatment guidelines and practice.